SoniVie, a company that is developing a system for the treatment of pulmonary arterial hypertension, recently raised an additional 2.5 million dollars from Israeli bio-medical fund Accelmed. With the new capital, SoniVie will fund the first in vivo trials for the treatment of pulmonary arterial hypertension, a severe disease that narrows the blood vessels connected to and within the lungs.